ConductScience.org, home

Paper22006014

Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.

Scosyrev E and 4 others. Cancer, 2012. Cited by 157 papers, by iCite.

Cite this record

ConductScience Library. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Papers, record 22006014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22006014

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.
PubMed
Journal
Cancer
PubMed
Year
2012
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
157
iCite
Relative citation ratio, by iCite
4.1
iCite
Revised in PubMed
2012-09-10
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Scosyrev EEmil
2Messing EMEdward M
3Mohile SSupriya
4Golijanin DDragan
5Wu GGuan

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Prostatic NeoplasmsMajor topic
Age Distribution
Aged
Aged, 80 and over
Humans
Incidence
Male
Middle Aged
Neoplasm Metastasis

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01859221Radiotherapy for Oligometastatic Prostate CancerBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in22006679A tale of 2 perspectives: the clinician and the public health professional.https://conductscience.org/library/papers/22006679PubMed
Comment in22579175Re: Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.https://conductscience.org/library/papers/22579175PubMed
Comment in22784726Re: Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.https://conductscience.org/library/papers/22784726PubMed

Download CSV of comments and corrections

Cited by75

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 157 citations.

PMIDTitleJournalYearIn PapersSource
42781478Predicting disease progression and mortality in prostate cancer using real-world data-driven time-inhomogeneous Markov models.iScience2026https://conductscience.org/library/papers/42781478PubMed
42255745Definitive Radiation Therapy for Older Adults With Localized Prostate Cancer.Cureus2026https://conductscience.org/library/papers/42255745PubMed
42154021[Reassessing androgen deprivation therapy (ADT) in older men with advanced prostate cancer: when to use, when to discontinue, and role as monotherapy?]Urologie2026https://conductscience.org/library/papers/42154021PubMed
42036417Advanced age increases cancer-specific mortality in bone-only metastatic prostate cancer: a SEER analysis.Sci Rep2026https://conductscience.org/library/papers/42036417PubMed
41801523Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer.EJNMMI Res2026https://conductscience.org/library/papers/41801523PubMed
41787493Outcomes of Retzius-sparing robot-assisted radical prostatectomy in men aged ≥ 75 years.BMC Urol2026https://conductscience.org/library/papers/41787493PubMed
41303903Elderly Men with De Novo Metastatic Castration-Sensitive Prostate Cancer: Therapy and Does Comorbidity Matter.Medicina (Kaunas)2025https://conductscience.org/library/papers/41303903PubMed
40720255Metabolic adaptations in cancer progression.Physiol Rev2026https://conductscience.org/library/papers/40720255PubMed
40150825Castration-Resistant Prostate Cancer Presenting as Bulky Lymphadenopathy: A Case without Bone Metastasis.Am J Case Rep2025https://conductscience.org/library/papers/40150825PubMed
40067073Evaluation of Mortality Risk Factors in Prostate Cancer: Impact of Demographic, Clinical, Laboratory, Therapeutic, and Trace Element Influences.Cancer Rep (Hoboken)2025https://conductscience.org/library/papers/40067073PubMed
39682181Survival Outcomes for Men over 80 Years Undergoing Transrectal Ultrasound-Guided Prostate Biopsy: A Prospective Analysis.Cancers (Basel)2024https://conductscience.org/library/papers/39682181PubMed
39641342A Rare Cause of Mechanical Icterus: Prostate Cancer Metastasis.Turk J Gastroenterol2024https://conductscience.org/library/papers/39641342PubMed
39040620Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?Eur Urol Open Sci2024https://conductscience.org/library/papers/39040620PubMed
38893199Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies.Cancers (Basel)2024https://conductscience.org/library/papers/38893199PubMed
38418470Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study.Sci Rep2024https://conductscience.org/library/papers/38418470PubMed
38291265Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.Curr Treat Options Oncol2024https://conductscience.org/library/papers/38291265PubMed
37658924Comprehensive geriatric assessment predicts radiation-induced acute toxicity in prostate cancer patients.Strahlenther Onkol2024https://conductscience.org/library/papers/37658924PubMed
37450026
Development and external validation of a novel prognostic nomogram for overall survival in prostate cancer patients with bone metastatic: a retrospective study of the SEER-based and a single Chinese center.
J Cancer Res Clin Oncol2023https://conductscience.org/library/papers/37450026PubMed
36864360225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings.Eur J Nucl Med Mol Imaging2023https://conductscience.org/library/papers/36864360PubMed
36291845Surgical Tolerability and Frailty in Elderly Patients Undergoing Robot-Assisted Radical Prostatectomy: A Narrative Review.Cancers (Basel)2022https://conductscience.org/library/papers/36291845PubMed

See all 75 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22006014

GET https://conductscience.org/api/papers/v1/22006014/cited_by?page=2